Ann: Continued Use of ResAppDx at COVID-19 Respiratory Clinic, page-186

You're going to be disappointed then. The FDA application for ResappDx is parked until the company resumes work on it. There's not going to be any left-field news on that front. If you're referring to the SleepCheck application, I believe you'll still be disappointed. Approval for SleepCheck might produce a short term spike, but the company's track record on commercialising its technology doesn't encourage any excitement based only on potential commercial success.

Which brings us to a key point regarding this stock. All milestones with the potential to cause a re-rate of the share price have either been achieved or have lapsed without producing the hoped-for results. There is nothing left in the pipeline at present. So any movement in the share price requires progress toward commercialisation.

And the company is clearly failing to gain any traction in this regard. CE Mark was granted for in August, 2019. TGA approval ResappDx was granted in October 2019 for paediatric use, and February 2020 for adult use.

Given that there are no known catalysts in view for significant re-rates, I think that the best we can hope for is a long, gradual, laborious climb in line with commercial progress. But a more likely outcome, based on this company's performance to day and the general case for med-tech startups, is a long, gradual, laborious struggle to nowhere; punctuated only by the occasional capital raise to keep the lights on.